ASH 2024 – Jennifer A. Woyach
Jennifer A. Woyach summarizes the current knowledge on BTK mutations and their clinical relevance in patients with CLL receiving BTK inhibitor therapy. She explains how patients fare after discontinuing BTK inhibitors due to toxicity and highlights the potential of next-generation BTK inhibitors, such as zanubrutinib, in combination with BCL-2 inhibitors like sonrotoclax for treatment-naïve CLL.
